ESC 365 - PCSK9 inhibitors in HIV patients with dyslipidemia

ESC Premium Access

PCSK9 inhibitors in HIV patients with dyslipidemia

Session: Liver metabolism and heart disease

Topic: Lipids

Speaker: Doctor S. Datla (Cleveland, US)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Doctor Sanjana Datla

University Hospitals Cleveland Medical Center, Cleveland (United States of America)

0 follower

6 more presentations in this session

Serum lipid profiles and uptake of lipid-lowering therapy in patients with premature atherosclerotic cardiovascular disease (ASCVD) in comparison to older patients with ASCVD

Speaker: Professor T. Tan (Sydney, AU)

Angioprotein-like 3 and atheroma progression in statin-treated type 2 diabetic patients with coronary artery disease: the pre-specified analysis from the OPTIMAL randomized controlled trial.

Speaker: Doctor S. Kitahara (Kashiwa, JP)

Circulating levels of amyloid-beta (1-40) peptide associate with cardiometabolic traits and risk for metabolic dysfunction-associated steatotic liver disease

Speaker: Doctor E. Aivalioti (Athens, GR)

The effect of 6-month treatment with coenzyme Q10 on endothelial, vascular and myocardial function in patients with nonalcoholic fatty liver disease.

Speaker: Doctor I. Ikonomidis (Athens, GR)

The association of steatotic liver disease with recurrent ischemic events in patients with chronic coronary syndrome: a multicenter cohort study

Speaker: Doctor G. Zeng (Beijing, CN)

Access the full session

Liver metabolism and heart disease

Speakers: Doctor S. Datla, Professor T. Tan, Doctor S. Kitahara, Doctor E. Aivalioti, Doctor I. Ikonomidis...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources